Total Funding
49
65
Total FundingPost-IPO Debt raised
Growth Score
-16 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
31084
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
- John Babcook: Distinguished FellowPast Role: Zymeworks, Senior Vice President, Discovery Research
Rhonda Wideman: Senior Director, Business Development & Alliance ManagementPast Role: Zymeworks, Manager, External R&D and Alliances
About the Company
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.
Zymeworks' approach combines proprietary molecular modeling and
simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.
It was founded in 2004 and headquartered in Vancouver, British Columbia.
